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Background and Objective. Allergy-like symptoms such as wheezing and eczema are common in young children and an early
diagnosis is important to initiate correct management. The objective of this study was to evaluate the diagnostic performance of
Phadiatop Infant, an in vitro test for determination of early sensitisation to food and inhalant allergens. Patients and Methods.T h e
study was conducted, retrospectively, using frozen sera from 122 children (median age 2.7 years) admitted to the hospital with
suspected allergic symptoms. The doctor’s diagnosis atopic/nonatopic was based on routinely used procedures such as clinical
evaluation,SPT,totalandallergen-speciﬁcIgEantibodies.TheperformanceofPhadiatopInfantwasevaluatedinablindedmanner
against this diagnosis. Results. Eighty-four of the 86 children classiﬁed as atopic showed a positive Phadiatop Infant test. Thirty-six
were classiﬁed as nonatopic, 32 of who had a negative test. With a prevalence of atopy of 70% in this population, this gives a
sensitivity of 98%, a speciﬁcity of 89%, and a positive and negative predictive value of 95% and 94%, respectively. Conclusion.T h e
results from the present study suggest that Phadiatop Infant could be recommended as a complement to the clinical information
in the diﬀerential diagnosis on IgE-mediated disease in young children with allergy-like symptoms.
Copyright © 2009 Ragnhild Halvorsen et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Allergic diseases are among the most common chronic dis-
eases throughout the world [1] and the prevalence of atopic
diseases in childhood has signiﬁcantly increased during the
past several decades [2, 3]. Although there is a general
consensus on the importance of a genetic predisposition for
atopic diseases, only changes in environmental factors can
explain this increase [4–6].
There is a strong association between sensitisation and
symptoms of allergic diseases although this association is not
absolute. The “allergy march” refers to the natural history of
sensitisation to allergens and symptoms of eczema, asthma,
and rhinitis, which is characterized by a typical sequence of
sensitisation and manifestations of symptoms that appear
during a certain age period [7, 8].
Food allergy and atopic eczema during the ﬁrst years of
life have been considered risk factors for subsequent asthma
and rhinitis caused by indoor and outdoor inhalant allergens
[5, 9, 10].
However,allergy-likesymptomsinchildhoodlikewheez-
ingandeczemaneednothaveanatopicbackground[11,12].
Wheezing episodes in young children are often transient and
associated with viral respiratory infections [13, 14].
Thus, better predictors of disease development and
diagnostic markers for allergic disease are needed to give
proper treatment and valuable advice, especially concerning
environmental control to parents of young children [15].
Thepresentstudywascarriedoutinordertoevaluatethe
diagnostic performance of Phadiatop Infant, an in vitro test
designed to detect allergen-speciﬁc IgE antibodies known to
be relevant in the development of IgE-sensitisation in early
childhood.
2. Patients andMethods
2.1. Patients. T h es t u d yw a sc o n d u c t e dr e t r o s p e c t i v e l yi n
consecutively included children, below the age of ﬁve years
and admitted to BKL Voksentoppen, Rikshospitalet, Oslo,2 International Journal of Pediatrics
during a period of twelvemonths. Thechildren werereferred
from paediatricians and other paediatric departments at
hospitals in Norway and thus selected for more severe
allergic symptoms. Frozen-serum samples from 122 children
were analysed and clinical data documented in the patients’
records were compiled for the study.
The study conformed to the principles of Helsinki’s
declaration and was approved by the local Ethics Committee.
2.2. Skin Prick Test. Skin Prick Test (SPT) was performed
accordingtostandardprocedureatthehospital.Glycerinated
allergen extract (Soluprick ALK-Abello, Denmark and a
standard lancet with 1mm tip and a shoulder (ALK-Abello,
Denmark) was used. Histamine chloride 10mg/mL was
used as positive-control and as negative-control glycerol.
The reaction was recorded as 3+ when the reaction was
equal to the histamine control, 2+ when half the histamine
control, and 4+ when double the histamine control. The
panel included egg white, cow’s milk, cod ﬁsh, peanut, hazel
nut, wheat, house dust mite, cat dander, birch, timothy,
Cladosporium, and latex.
2.3. Total and Allergen-Speciﬁc IgE Antibodies. Total and
allergen-speciﬁc IgE antibodies were determined in Immun-
oCAP 100 (Phadia AB, Sweden) at the hospital labora-
tory when appropriate according to clinical ﬁndings. The
instructions from the manufacturer were followed. The same
allergen panel as for SPT was analysed.
2.4.ImmunoCAPPhadiatop,fx5,andImmunoCAPPhadiatop
Infant. Serum samples were sent to Phadia AB, Uppsala,
Sweden, for determination of speciﬁc IgE antibodies using
ImmunoCAP Phadiatop, fx5 (a food mixture of milk, egg
white, ﬁsh, peanut, wheat, and soy bean), and ImmunoCAP
Phadiatop Infant using ImmunoCAP100 (Phadia AB, Upp-
sala, Sweden). Results ≥ 0.35kA/l were considered positive.
Phadiatop Infant is designed to detect allergen-speciﬁc
IgE antibodies to food and inhalant allergens, relevant in
the development of IgE-mediated disease in young children.
The following allergens are included in the test: hen’s egg,
cow’s milk, peanut, shrimp, cat epithelium and dander, dog
dander, house dust mite, common silver birch, timothy,
ragweed, and wall pellitory. The laboratory analyses were
performed in a blinded manner and the results of Phadiatop
and fx5 were sent back to the investigating physician.
2.5. Diagnostic Procedures. Atopy was deﬁned as a consti-
tutional disposition to produce IgE antibodies to common
allergens whether the patients had clinical symptoms or not,
asjudgedbytheInvestigator.Thestudywasdesignedtomake
the diagnosis with best possible available tools (case history,
SPT, and allergen-speciﬁc IgE results) to evaluate the clinical
performance of Phadiatop Infant.
A preliminary diagnosis whether a child was atopic or
not was assessed by the investigating physician in retrospect,
taking into account clinical history and diagnostic proce-
dures, which includes available SPT and allergen-speciﬁc IgE
results, noted in the patient records. In the ﬁnal diagnosis
of the atopic state, the laboratory results from Phadiatop
and fx5 were also taken into consideration in order to get
comparable data of allergen-speciﬁc IgE sensitisation on
all children. This ﬁnal diagnosis was used as the reference
for calculation of the diagnostic performance of Phadiatop
Infant.
2.6. Statistical Analysis. Processing of data and statistical
analyses were performed using SAS statistical software sys-
tem. Demographic data were analysed descriptively. Quan-
titative variables are described in appropriate measures of
localisation and dispersion, quantitatively variables pre-
sented by counts and percentages. The diagnostic perfor-
mance of Phadiatop Infant was evaluated by calculating
sensitivity, speciﬁcity, negative and positive predictive values
(NPV, PPV), respectively, with 95% conﬁdence intervals.
The subgroups divided by age, <2y e a r sa n d≥2y e a r sw e r e
compared with regard to the diagnostic performance of
Phadiatop Infant using descriptive statistics.
3. Results
The demographic characteristics of the children classiﬁed
according to the ﬁnal diagnosis of atopy/nonatopy or incon-
clusive diagnosis are shown in Table 1. Thirty-eight (31%)
subjectsinthestudypopulationweregirlsand84(69%)were
boys with a median age of 2.7 years. Of the 122 children, 86
(70%)wereatopic,26girlsand60boys,whichisacommonly
found gender distribution among atopic children at that age.
No diﬀerenceinmedianagewasobservedbetweentheatopic
and nonatopic children.
Only 18% of the children presented with wheezing
as a single symptom and the majority of these children
were nonatopic, 55% below 2 years and 40% above this
age, respectively. Eczema as a single symptom was the
most prevalent symptom among the children below two
years of age (49%) and 63% were classiﬁed as atopic. In
the older age group of children, eczema and/or wheezing
in combination with other allergic symptoms dominated
(41%) and 48% were classiﬁed as atopic. Other allergy-like
symptoms such as rhinitis, rhinoconjunctivitis, anaphylaxis,
and gastrointestinal symptoms were registered in 31 (26%)
children,outofwhom22(71%)wereolderthan2years(data
not shown).
Eighty-three of the children (68%) reported at least one
ﬁrst degree relative, with about the same proportion for
the atopic as for the nonatopic children, 71% and 61%,
respectively (data not shown).
The diagnostic performance characteristics of Phadiatop
Infant in this study population with a prevalence of 70%
are presented in Table 2. The sensitivity calculated for the
whole group of children was 98% (95% CI: 92–100%) and
the speciﬁcity 89% (95%CI: 74–97%). The PPV and NPV
values were 95% (95% CI: 89–99%) and 94% (95% CI: 80–
99%), respectively. The diagnostic performance of the test
was found to be similar when the children were separated
in the two age groups, below or above two years, but due to
small numbers of children in the separated age groups, the
calculated values are not presented.International Journal of Pediatrics 3
Table 1: Distribution of patients by atopic classiﬁcation, gender and age.
Patient group Total n (%) Gender female/male n (%) Age years median (min-max)
Atopic 86 (70) 26 (30)/60 (70) 2.7 (0.7–4.7)
Nonatopic 36 (30) 12 (33)/24 (67) 2.6 (0.5–4.6)
Total 122 (100) 38 (31)/84 (69) 2.7 (0.5–4.7)
Table 2: Diagnostic performance characteristics of Phadiatop Infant. Data are given as number of children.
Phadiatop Infant
test result
Total All ages <2 years ≥2 years
Atopic∗∗ Nonatopic∗∗ Atopic∗∗ Nonatopic∗∗ Atopic∗∗ Nonatopic∗∗
Positive 88 84 4 30 1 54 3
Negative 3 4 23 20 9 22 3
Total 122 86 36 30 10 56 26
∗∗Atopic/nonatopic was classiﬁed prior to Phadiatop Infant was analysed.
4. Discussion
Symptoms of allergic disease in young children are generally
unspeciﬁc and the diagnosis without objective tests could be
an arbitrary process. The paediatric section of the European
Academy of Allergy and Clinical Immunology has recently
publishedapositionpaperwithrecommendationsonallergy
testinginchildrentoimprovetheidentiﬁcationofallergyand
quality of care [16].
An earlier published study has shown that 76 out of
147 children could not be classiﬁed as having an IgE-
mediated disease or not, based on case history and physical
examination alone. Allergen-speciﬁc IgE tests reduced this
number to 8 [17]. Similar results were found in a recently
published study, where measurements of IgE-antibodies,
added to case history and physical examinations, highly
improved the discrimination between IgE- and non-IgE-
mediated diseases in young children [18]. The results from
our study conﬁrm these ﬁndings and suggest that Phadiatop
Infant could be a useful tool for discrimination between
atopy/non-atopy. A positive Phadiatop Infant test should
however be followed by allergen-speciﬁc antibody testing to
a selected panel to identify the oﬀending allergen(s) [19, 20].
The test seems to be at least as useful among the youngest
children, below two years, as among children at 2–4 years of
age. The youngest child in the study was 6 months, which
conﬁrms ﬁndings from other publications that allergen-
speciﬁc IgE-antibodies can be detected early in life [17, 18,
21]. These ﬁndings support the value of testing children with
allergy-like symptoms at an early age.
Family history has been considered an important risk
factor for atopy and has been widely used for prediction of
allergy and allergic diseases [9]. The results from our study
are in good agreement with the notion that allergy/atopy is
extremely commonly found. On the other hand, the fact that
30% of the atopic children did not have a family history of
allergy agrees with investigators claiming that a great portion
of newly diagnosed allergics/atopics do not have a family
history of allergy/atopy [4]. Thus it could be stated that
family history is no longer practical in predicting allergic
disease.
This study population represents a selected cohort as
Voksentoppen is a hospital having referred patients with
allergy-like symptoms and allergic diseases from general
paediatricians in the whole country, often of a more severe
character. This explains the unusual high prevalence of
atopy, 70%, in this population. However, other studies have
shownthatPhadiatop Infantcouldbeapplied in populations
with a lower prevalence of atopy, still demonstrating good
performance characteristics [17, 18, 21].
The clinical appearance of allergy in our study is in
agreement with the concept of the allergy march and
supports what has been reported earlier from other studies
[7, 8]. Eczema was the predominating symptom among
the atopic children below 2 years. Thus, eczema was not
common in the nonatopic group of children and only one
of the 31 children with eczema was classiﬁed as nonatopic.
The progression from eczema to other allergic problems was
also demonstrated in this study. Eighty-six percent of the
children with eczema and wheezing in combination with
other symptoms were found in the older age group and as
many as 82% were classiﬁed as atopic.
Themajorityofchildren,allages,presentingwithwheez-
ing were nonatopic (73%). Many infants and children who
wheeze have transient conditions associated with diminished
airway function and do not have an increased risk of asthma
later in life. However, children with persistent wheezing,
starting during the ﬁrst years of life, and with an atopic
heredity, should be considered being at risk for asthma later
during childhood [11, 22, 23]. Therefore, an early diagnosis
of IgE sensitisation may be important for the choice of
treatment to wheezing toddlers.
Childrenwithallergicsymptomsusuallypresentatagen-
eral paediatrician who needs to discriminate which patients
have to be sent to an allergist for further evaluation. Possible
diagnostics interventions to avoid unnecessary referrals are
discussed in a recently published paper. Rule-out tests with a
high discriminating potential aresuggested to have a gateway
function to fulﬁl this diﬀerentiation and an important role
to prevent the march of allergic children from the ﬁrst to
secondary level of care [24].4 International Journal of Pediatrics
The present study shows that Phadiatop Infant has a
diagnostic performance with a high sensitivity and speci-
ﬁcity.Thus, thetestcouldberecommendedasacomplement
to the clinical information in the diﬀerential diagnosis on
IgE-mediated disease in young children with allergy-like
symptoms. Furthermore, the test could be useful in assisting
primary care physicians in selecting atopic children at an
early stage for further intervention or referral to an allergist.
An early correct diagnosis will thus allow for better
management and a possibility to delay or even prevent the
onset of asthma in children with eczema and the avoidance
of further deterioration of lung function in children with
asthma [16, 25].
Acknowledgment
This study was supported by Phadia AB, Uppsala, Sweden.
References
[1] J. Bousquet, “Allergy as a global problem: ‘think globally, act
globally’,” Allergy, vol. 57, no. 8, pp. 661–662, 2002.
[ 2 ]S .H .D o w n s ,G .B .M a r k s ,R .S p o r i k ,E .G .B e l o s o u v a ,N .G .
Car, and J. K. Peat, “Continued increase in the prevalence of
asthma and atopy,” Archives of Disease in Childhood, vol. 84,
no. 1, pp. 20–23, 2001.
[3] M. Law, J. K. Morris, N. Wald, C. Luczynska, and P. Burney,
“Changes in atopy over a quarter of a century, based on cross
sectional data at three time periods,” British Medical Journal,
vol. 330, no. 7501, pp. 1187–1188, 2005.
[4] U. Wahn, “What drives the allergic march?” Allergy, vol. 55,
no. 7, pp. 591–599, 2000.
[5] A. Høst and S. Halken, “The role of allergy in childhood
asthma,” Allergy, vol. 55, no. 7, pp. 600–608, 2000.
[6] M. N. Blumenthal, “The role of genetics in the development
of asthma and atopy,” Current Opinion in Allergy and Clinical
Immunology, vol. 5, no. 2, pp. 141–145, 2005.
[7] S. Illi, E. von Mutius, S. Lau, et al., “The natural course of
atopic dermatitis from birth to age 7 years and the association
with asthma,” Journal of Allergy and Clinical Immunology, vol.
113, no. 5, pp. 925–931, 2004.
[8] J. M. Spergel, “Atopic march: link to upper airways,” Current
Opinion in Allergy and Clinical Immunology, vol. 5, no. 1, pp.
17–21, 2005.
[9] M. Kulig, R. Bergmann, B. Niggemann, G. Burow, and U.
Wahn, “Prediction of sensitization to inhalant allergens in
childhood: evaluating family history, atopic dermatitis and
sensitization to food allergens,” Clinical and Experimental
Allergy, vol. 28, no. 11, pp. 1397–1403, 1998.
[10] G. Roberts, N. Patel, F. Levi-Schaﬀer, P. Habibi, and G. Lack,
“Food allergy as a risk factor for life-threatening asthma in
childhood: a case-controlled study,” Journal of Allergy and
Clinical Immunology, vol. 112, no. 1, pp. 168–174, 2003.
[11] F. D. Martinez, A. L. Wright, L. M. Taussig, et al., “Asthma and
wheezing in the ﬁrst six years of life,” The New England Journal
of Medicine, vol. 332, no. 3, pp. 133–138, 1995.
[12] A. L. Wright, “Epidemiology of asthma and recurrent wheeze
inchildhood,”ClinicalReviewsinAllergyandImmunology,vol.
22, no. 1, pp. 33–44, 2002.
[13] P.G.HoltandP.D.Sly,“Interactionsbetweenrespiratorytract
infections and atopy in the aetiology of asthma,” European
Respiratory Journal, vol. 19, no. 3, pp. 538–545, 2002.
[14] M. M. H. Kusel, N. H. de Klerk, T. Kebadze, et al., “Early-
life respiratory viral infections, atopic sensitization, and risk
of subsequent development of persistent asthma,” Journal of
Allergy and Clinical Immunology, vol. 119, no. 5, pp. 1105–
1110, 2007.
[15] M. Wickman, E. Mel´ en, N. Berglind, et al., “Strategies for
preventing wheezing and asthma in small children,” Allergy,
vol. 58, no. 8, pp. 742–747, 2003.
[16] A. Høst, S. Andrae, S. Charkin, et al., “Allergy testing in
children: why, who, when and how?” Allergy,v o l .5 8 ,n o .7 ,
pp. 559–569, 2003.
[17] A. Fiocchi, R. Besana, A.-C. Ryd´ en, et al., “Diﬀerential
diagnosis of IgE-mediated allergy in young children with
wheezing or eczema symptoms using a single blood test,”
Annals of Allergy, Asthma and Immunology, vol. 93, no. 4, pp.
328–333, 2004.
[18] S. Lau, M. Nilsson, C. Sulser, G. Schulz, M. P. Borres, and
U. Wahn, “Use of Phadiatop Infant in diagnosis of speciﬁc
sensitization in young children with wheeze or eczema,”
Pediatric Allergy and Immunology, vol. 19, no. 4, pp. 337–341,
2008.
[19] S. Ahlstedt, “Understanding the usefulness of speciﬁc IgE
blood tests in allergy,” Clinical and Experimental Allergy, vol.
32, no. 1, pp. 11–16, 2002.
[20] M. Wickman, S. Ahlstedt, G. Lilja, and M. van Hage Hamsten,
“Quantiﬁcation of IgE antibodies simpliﬁes the classiﬁcation
of allergic diseases in 4-year-old children. A report from the
prospective birth cohort study—BAMSE,” Pediatric Allergy
and Immunology, vol. 14, no. 6, pp. 441–447, 2003.
[21] N. Ballardini, C. Nilsson, M. Nilsson, and G. Lilja,
“ImmunoCAP
TM Phadiatop Infant—a new blood test for
detecting IgE sensitisation in children at 2 years of age,”
Allergy, vol. 61, no. 3, pp. 337–343, 2006.
[22] L. M. Taussig, A. L. Wright, C. J. Holberg, M. Halonen, W.
J. Morgan, and F. D. Martinez, “Tucson children’s respiratory
study: 1980 to present,” Journal of Allergy and Clinical
Immunology, vol. 111, no. 4, pp. 661–675, 2003.
[23] L. A. Lowe, A. Simpson, A. Woodcock, J. Morris, C. S. Murray,
and A. Custovic, “Wheeze phenotypes and lung function
in preschool children,” American Journal of Respiratory and
Critical Care Medicine, vol. 171, no. 3, pp. 231–237, 2005.
[24] A. Fiocchi, G. R. Bouygue, L. Terracciano, T. Sarratud,
and A. Martelli, “Ruling out food allergy in pediatrics and
preventing the “march” of the allergic child,” Allergy and
Asthma Proceedings, vol. 27, no. 4, pp. 306–311, 2006.
[25] S. T. Holgate and G. Lack, “Improving the management of
atopic disease,” Archives of Disease in Childhood, vol. 90, no.
8, pp. 826–831, 2005.